Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
- 463 Downloads
Background In the clinical development of oncology drugs, the recommended dose is usually determined using a 3 + 3 dose-escalation study design. However, this phase I design does not always adequately describe dose-toxicity relationships. Methods 125 patients, with either solid tumours or lymphoma, were included in the study and 1217 platelet counts were available over three treatment cycles. The data was used to build a population pharmacokinetic/pharmacodynamic (PKPD) model using a sequential modeling approach. Model-derived Recommended Doses (MDRD) of abexinostat (a Histone Deacetylase Inhibitor) were determined from simulations of different administration schedules, and the higher bound for the probability of reaching these MDRD with a 3 + 3 design were obtained. Results The PKPD model developed adequately described platelet kinetics in both patient populations with the inclusion of two platelet baseline counts and a disease progression component for patients with lymphoma. Simulation results demonstrated that abexinostat administration during the first 4 days of each week in a 3-week cycle led to a higher MDRD compared to the other administration schedules tested, with a maximum probability of 40 % of reaching these MDRDs using a 3 + 3 design. Conclusions The PKPD model was able to predict thrombocytopenia following abexinostat administration in both patient populations. A model-based approach to determine the recommended dose in phase I trials is preferable due to the imprecision of the 3 + 3 design.
KeywordsAbexinostat Thrombocytopenia PKPD model Recommended Dose Simulation Disease progression
Acknowledgments and disclosures
Authors would like to thank Pharmacyclics for providing data from the PCYC-402 and the PCYC-403 clinical studies.
Author’s disclosures of potential conflicts of interest: Quentin Chalret du Rieu, Sylvain Fouliard, Ioana Kloos and Marylore Chenel are employed by Institut de Recherches Internationales Servier. The other author (s) indicated no potential conflicts of interest.
This work was integrated in a Ph. D. project (Quentin Chalret du Rieu), granted by Institut de Recherches Internationales Servier.
We thank Ms Katie Owens for her editorial assistance.
- 12.Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137–1146PubMedGoogle Scholar
- 13.Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RS (2002) The bleeding risk index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer 94:3252–3262CrossRefPubMedGoogle Scholar
- 16.Gaydos, L. A., Freireich, E. J., Mantel, N. (3-5-1962) The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905–909Google Scholar
- 21.Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelievre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N (2013) Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis 4:e738PubMedCentralCrossRefPubMedGoogle Scholar
- 22.Chalret du Rieu Q, Fouliard S, Jacquet-Bescond A, Robert R, Kloos I, Depil S, Chatelut E, Chenel M (2013) Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781). a new histone deacetylase inhibitor. Pharm Res 30:2640–2653CrossRefPubMedGoogle Scholar
- 26.Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D, Loriot Y, Hollebecque A, Kloos I, Soria JC, Chenel M, Depil S (2013) Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Eur J Cancer 49:2791–2797CrossRefPubMedGoogle Scholar
- 30.Van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225–234CrossRefPubMedGoogle Scholar
- 35.Hitchcock, I. S., Kaushansky, K. (2014) Thrombopoietin from beginning to end. Br J Haematol.Google Scholar